Australia Neuroendocrine Carcinoma Market Size, Share, Growth and Forecast, 2025-2035

Funded PRRT and rising diagnoses lift NEN treatment value

The Australia neuroendocrine carcinoma market was valued at USD 41.5 million in 2025 and is projected to increase from USD 52.0 million in 2026 to USD 119.9 million by 2035, registering a CAGR of 9.73% during 2026–2035. Demand comes from a growing number of Australians diagnosed with gastrointestinal, pancreatic and lung neuroendocrine neoplasms, specialist teams that prescribe long-acting somatostatin analogues, and nuclear medicine centers that deliver peptide receptor radionuclide therapy. New South Wales and the Australian Capital Territory held the largest regional share, 34.5% in 2025, because Sydney hosts designated public treatment services and large private imaging groups. Queensland is the fastest-growing region at 10.10% a year, as population growth adds older patients. In turn, a new Medicare item for lutetium-177 DOTA treatment took effect on Nov. 1, 2025, which lowers out-of-pocket costs for eligible patients in public and private settings.

Which neuroendocrine cancer treatments does the estimate cover?

The estimate measures the value of medicines, radionuclide therapy and diagnostic services used to manage neuroendocrine neoplasms in Australia, including well-differentiated tumors and poorly differentiated carcinomas. It covers somatostatin analogues, peptide receptor radionuclide therapy, targeted therapies, cytotoxic chemotherapy and diagnostic services such as somatostatin receptor PET imaging. Values include treatment paid by public budgets, private institutions and self-paying patients.

The estimate excludes surgery fees, general hospital bed costs, palliative care services and supportive medicines that are not specific to neuroendocrine disease. The value chain runs from drug sponsors, isotope producers and compounding facilities through hospital pharmacies and specialty distributors to multidisciplinary teams, nuclear medicine departments and imaging groups that diagnose and treat patients.

Somatostatin analogues lead while PRRT grows fastest

Why do somatostatin analogues lead product demand?

Based on product type, the market is categorized into somatostatin analogues, PRRT, targeted therapies, cytotoxic chemotherapy and diagnostic services. Somatostatin analogues led with a 38.0% share of 2025 value, because most patients with well-differentiated disease receive monthly long-acting injections for many years. PRRT grows fastest at 11.54% a year, as Medicare funding and a registered product widen access to radionuclide therapy.

How do tumor sites split treatment value?

Based on disease area, the market is categorized into gastrointestinal NENs, pancreatic NENs, thoracic NENs and extra-gastrointestinal non-thoracic NENs. Gastrointestinal NENs led with a 44.0% share of 2025 value, because small bowel, appendix and rectal tumors make up the largest patient group. Pancreatic NENs grow fastest at 10.14% a year, as pancreatic patients use more targeted therapy and lutetium treatment.

Why does outpatient specialist care hold most value?

Based on care setting, the market is categorized into inpatient treatment, outpatient specialist care and community treatment. Outpatient specialist care led with a 55.0% share of 2025 value, because injections, imaging and most lutetium cycles are delivered in day units and clinics. Community treatment grows fastest at 10.22% a year, as community pharmacies can now start long-acting lanreotide treatment.

How do public and private purchasers fund treatment?

Based on customer type, the market is categorized into public purchasers, private institutional purchasers and self-paying patients. Public purchasers led with a 62.0% share of 2025 value, because PBS, Medicare and state hospital budgets pay for most medicines and therapy. Private institutional purchasers grow fastest at 9.93% a year, as private nuclear medicine groups bill the new Medicare items.

Medicare PRRT funding and new registrations drive demand

How does funded PRRT access widen treatment?

Funded PRRT access widens treatment, because patients no longer depend on state budgets or charity support to receive lutetium therapy. A new Medicare item 16060 for one lutetium-177 DOTA treatment cycle took effect on Nov. 1, 2025, with a fee of $9,999.95, according to the Medicare factsheet. The benefit reaches $9,895.45 at the 85% rate, which covers most of the listed fee. The item is not limited to a single product type, so compounded and registered doses both qualify. As a result, PRRT grows at 11.54% a year, the fastest product rate, as private and public nuclear medicine centers add treatment slots for eligible patients.

Why does an expanding diagnosed patient base lift demand?

An expanding diagnosed patient base lifts demand, because more Australians receive a neuroendocrine diagnosis each year and many live with the disease for a long time. Cancer Australia estimated 5,437 new cases in 2022, up from 4,508 in 2018, according to national cancer statistics. The age-standardized rate rose to 17 per 100,000 people from 9.0 in 1982. Five-year relative survival also reached 51% for 2014 to 2018, compared with 22% for 1989 to 1993, which shows how treatment now extends over many years. In turn, gastrointestinal NENs hold a 44.0% share of 2025 value, as long-term patients need repeat imaging and years of maintenance therapy.

Download Free Sample

How does registered radiopharmaceutical availability help?

Registered radiopharmaceutical availability helps demand, because hospitals can now choose a product reviewed by the national regulator. The TGA approved Lutathera from Novartis Pharmaceuticals Australia on Nov. 14, 2025, and entered it on the ARTG on Nov. 17, 2025, according to the public assessment report. The approved indication covers somatostatin receptor-positive gastroenteropancreatic tumors in adults. The regulator had accepted the application for evaluation in September 2024, after Novartis lodged a new medicine submission. Registration gives hospitals and private centers a product with a public quality and safety review. As a result, private institutional purchasers grow at 9.93% a year, as private centers add registered lutetium doses alongside wider radiopharmaceutical supply.

Why does community access to lanreotide sustain volumes?

Community access to lanreotide sustains volumes, because patients in regional areas can start treatment closer to home. The PBS listing that allows community access initiation of Somatuline Autogel took effect on Nov. 1, 2024, according to the PBS listing record. The advisory committee said the change would improve access for patients in rural and remote areas. Its review counted between 500 and 5,000 lanreotide patients a year in 2022 and 2023, with estimated market growth of 8% a year, which points to steady new patient starts. In turn, somatostatin analogues hold a 38.0% share of 2025 value, as long-acting somatostatin analog injections remain first-line care.

Imaging-led care and local isotope supply reshape treatment

How is the shift to imaging-led care changing treatment?

The shift to imaging-led care is changing treatment, because doctors now select therapy from receptor PET scans rather than from symptoms alone. Medicare item 61530 for a whole-body gallium-68 DOTA PET scan carries a fee of $953.00 from Nov. 1, 2025. The scan stages disease, confirms receptor expression before therapy, tracks response and checks suspected recurrence. Eligibility for lutetium treatment also requires review by a formal multidisciplinary board with at least one oncologist and one surgeon. As a result, diagnostic services keep a steady share of value, as each therapy course needs repeat cancer imaging before and after treatment.

Why is the rise of local isotope production important?

The rise of local isotope production is important, because lutetium doses decay quickly and need short supply chains. ANSTO and Cyclotek announced Applied Molecular Therapies in November 2021 to build what they described as Australia's first GMP theranostics facility, starting in Melbourne. The venture planned to make therapeutic radiopharmaceuticals, initially focused on non-carrier-added lutetium-177. In addition, the new Medicare item covers more than one Lu-DOTA product type, which keeps local compounding viable. The TGA also entered Lutathera on the ARTG on Nov. 17, 2025, adding a registered imported option. In turn, outpatient specialist care holds a 55.0% share of 2025 value, as reliable local doses let centers schedule lutetium cycles as day treatment.

Download Free Sample

Can regional and remote patient access open new growth?

Regional and remote patient access offers a growth path, because many patients still travel long distances for therapy. The Queen Elizabeth Hospital in Adelaide is the only center in South Australia or the Northern Territory that delivers lutetium therapy. Its service has given 1,000 doses to 229 patients since April 2011, and one in four patients travels from regional or remote areas. The PBS change for lanreotide also targets rural and remote patients. As a result, community treatment grows at 10.22% a year, the fastest care setting rate, as more care moves closer to where patients live.

Is there room to grow care for long-term survivors?

Care for long-term survivors has room to grow, because better survival means more patients need years of monitoring and repeat therapy. About 24,285 people diagnosed between 1982 and 2017 were still alive at the end of 2017. Central Adelaide health services also report that more than 29,000 Australians now live with neuroendocrine cancer. Lifetime risk to age 85 reached 1 in 55 in the 2022 estimate, which keeps the patient pool growing. In turn, pancreatic NENs grow at 10.14% a year, the fastest disease area rate, as survivors cycle through targeted therapy, lutetium treatment and other cancer drugs.

Cycle costs, few centers and generics test suppliers

How do high cycle costs limit uptake?

High cycle costs limit uptake, because each lutetium cycle carries a fee close to $10,000 and patients often need several cycles. Claims of $10,000 or more must be lodged on paper or in person rather than online. As a result, some patients face upfront payments before the Medicare benefit arrives. Providers respond with bulk billing for eligible patients, clear cost quotes before each cycle and staff who help patients complete paper claims. Hospital social workers also link patients with charity and travel funds that cover gaps.

Why do few treatment centers slow access?

Few treatment centers slow access, because lutetium therapy needs shielded rooms, trained staff and licensed isotope handling. New South Wales has only two designated public services, at Royal North Shore Hospital and St George Hospital. In turn, patients in outer suburbs and regional towns travel for each cycle. Health services respond with travel support, patient accommodation near hospitals and new private nuclear medicine sites. Each new site needs isotope supply contracts, radiation licenses and trained nuclear medicine physicians before it can open.

How does generic competition pressure analog prices?

Generic competition pressures analog prices, because the first generic lanreotide, Mytolac, was listed on the PBS on Aug. 1, 2023. Price cuts that follow generic entry reduce value per injection for originator brands. As a result, somatostatin analogue value grows more slowly than patient numbers. Sponsors respond with device improvements, patient support programs and community access listings that widen use. Generic suppliers, in turn, compete on price and supply reliability for hospital and community pharmacy contracts.

Why does late diagnosis complicate treatment?

Late diagnosis complicates treatment, because neuroendocrine tumors often grow slowly and cause vague symptoms for years. Some patients are diagnosed only after the disease has spread to the liver or other organs. In turn, treatment costs rise and fewer patients can have curative surgery. Specialist groups respond with awareness campaigns, nurse support lines and faster referral pathways to multidisciplinary teams. Wider use of receptor PET imaging also helps doctors confirm the diagnosis and stage the disease earlier.

New South Wales leads while Queensland grows fastest

Why do New South Wales and the ACT hold the largest share?

New South Wales and the Australian Capital Territory held a 34.5% share of 2025 value and grow at 9.50% a year, because Sydney hosts designated lutetium services at Royal North Shore Hospital and St George Hospital. The two jurisdictions had about 9.16 million residents at March 31, 2026. However, growth is slower than in other zones, as New South Wales grew only 1.1% in the year to March 2026. In turn, the zone keeps the largest share because both designated public services sit in the Sydney area.

How do Victoria and Tasmania support treatment demand?

Victoria and Tasmania held a 29.0% share of 2025 value and grow at 9.60% a year, because Melbourne hosts the Peter MacCallum Cancer Centre and a planned local theranostics facility. The two states had about 7.73 million residents at March 31, 2026. Victoria also added about 109,500 residents in the year, which supports steady growth in diagnosed patients. In turn, Credence Research expects local lutetium production to support more treatment slots in the zone.

Download Free Sample

Why does Queensland grow fastest?

Queensland accounted for 18.5% of 2025 value and grows fastest at 10.10% a year, because the state added about 90,100 residents in the year to March 2026. Its population reached about 5.74 million, and growth of 1.6% adds older residents who face higher cancer risk. As a result, demand for imaging and maintenance therapy rises quickly. Credence Research expects new private imaging and therapy capacity in the state to follow this population growth.

How do Western Australia, South Australia and the NT build demand?

Western Australia, South Australia and the Northern Territory accounted for 18.0% of 2025 value and grow at 10.00% a year, because Adelaide and Perth run specialist centers for wide catchments. The Queen Elizabeth Hospital is the only lutetium center for South Australia and the Northern Territory. Western Australia also posted the fastest state population growth at 2.1% in the year to March 2026.

Download Free Sample

Registrations, listings and funding moves from 2024 to 2026

Ga-68 imaging and lutetium therapy reshape NEN care

• Gallium-68 DOTA PET imaging maps somatostatin receptor expression across the body, which guides staging, patient selection and response checks after each lutetium treatment course.
• Lutetium-177 DOTA therapy delivers radiation directly to receptor-positive tumor cells, which slows progression in advanced disease and can ease hormone symptoms in functioning tumors.
• Long-acting peptide injections release somatostatin analogues over four weeks, which controls hormone symptoms and tumor growth, and generic versions now lower the cost per dose.
• Oral targeted therapies block growth signals inside tumor cells, which offers another option for advanced pancreatic disease when injections or lutetium therapy stop working.

Drug sponsors and nuclear medicine centers share the field

Competition combines drug sponsors that supply long-acting injections and targeted medicines with nuclear medicine centers that deliver lutetium therapy. Novartis Pharmaceuticals Australia received TGA approval for Lutathera in November 2025. Ipsen sponsors Somatuline Autogel, which gained community access initiation on the PBS in November 2024. Pfizer's Sutent has carried a PBS listing for metastatic pancreatic tumors since 2013. Applied Molecular Therapies was formed by ANSTO and Cyclotek, which announced the venture in November 2021, to make lutetium radiopharmaceuticals in Melbourne. Peter MacCallum Cancer Centre and Royal North Shore Hospital run specialist programs that treat referred patients. Rivals compete on product registration, PBS and Medicare listings, isotope supply reliability, treatment capacity and support for regional patients. Generic suppliers add price pressure on older medicines, while private imaging groups compete for funded PET scans and therapy cycles under the new Medicare items.

Companies profiled and their roles in this market

Credence Research view on Australian NEN treatment

Credence Research's view is that Australian neuroendocrine treatment value will grow quickly because funding, registration and diagnosis trends now point in the same direction. Medicare funding of lutetium therapy removes the main cost barrier, while a registered product gives private centers a reliable supply option. Somatostatin analogues remain the base of care, although generic pricing slows their value growth. Suppliers and centers that combine receptor imaging, steady isotope supply and regional outreach should gain share fastest.

How the Australian NEN treatment estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines national cancer incidence and survival statistics, Medicare and PBS listing documents, TGA assessment reports, state health service releases, World Bank health spending data, population statistics and company announcements. Segment splits, regional zones, regional shares and growth rates are Credence Research estimates, because the client sheet named only the eastern seaboard. Sources used are public reports, official statistics and company releases, and no interviews or surveys were used.

Theranostics and longer survival carry growth to 2035

Treatment value is expected to reach USD 119.9 million by 2035, a 9.73% CAGR during 2026–2035, as funded lutetium therapy, receptor imaging and longer survival keep demand rising. Growth should be strongest through 2028 as Medicare-funded cycles replace self-paid and charity-funded treatment. After that, wider imaging use and new centers in growing states will carry more growth. Australia already spent about 10.4% of GDP on health in 2023, according to World Bank data, which supports continued funding for specialist cancer care.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.